BioMarin's Phase 3 trial of ENPP1 enzyme therapy fails to show benefit

BioMarin reported that its late-stage study of an enzyme replacement therapy for ENPP1 deficiency did not meet its primary efficacy endpoints. The trial, which enrolled patients lacking the ENPP1 enzyme, aimed to increase plasma inorganic pyrophosphate levels and improve clinical outcomes.

The data showed mixed results, with no clear clinical improvement observed in the treated group compared with placebo. While some biochemical markers changed, the overall benefit was insufficient to support regulatory approval.

The outcome underscores the challenges of developing treatments for rare genetic disorders and may delay BioMarin's plans to bring the therapy to market. The company will likely reassess the program and consider next steps, including possible additional studies or alternative approaches.

Investors and clinicians will be watching how BioMarin responds, as the negative readout could impact the company's pipeline momentum and financial outlook.